PHN: postherpetic neuralgia.
Not an actual patient.
Favorable safety profile1
Adverse Reaction Incidence (%) in Controlled Double-blind Trials in Postherpetic Neuralgia
(Events in >1% of QUTENZA-treated Patients and at Least 1% Greater in the QUTENZA Group than in the Control Group)
|General Disorders and Administration Site Conditions|
|Application site erythema||63||54|
|Application site pain||42||21|
|Application site pruritus||6||4|
|Application site papules||6||3|
|Application site edema||4||1|
|Application site swelling||2||1|
|Application site dryness||2||1|
|Infections and Infestations|
|Skin and Subcutaneous Tissue Disorder|
Most common adverse reactions (≥5% and greater than control) are highlighted: application site erythema, application site pain, application site pruritus, and application site papules.
Transient increases in blood pressure (average <10 mm Hg) may occur in patients during and shortly after the QUTENZA treatment. Monitor blood pressure during and following the treatment procedure.
Patients with unstable or poorly controlled hypertension or a recent history of cardiovascular or cerebrovascular events may be at an increased risk of adverse cardiovascular effects. Consider these factors prior to initiating QUTENZA treatment.
The most common adverse reactions were transient and self-limited.1
QUTENZA has a favorable safety profile with no systemic drug-drug interactions
- QUTENZA can be used alone or in combination
Low risk for systemic side effects1
- QUTENZA is non-systemic
- QUTENZA is non-opioid
- QUTENZA has no contraindications
Low discontinuation rates1
- 1% of QUTENZA patients discontinued in clinical studies due to an adverse event
Patients may experience the following1:
- Pain at treatment site, which can be treated with a cooling pack or appropriate analgesic medication, if needed
- Transient increase in blood pressure
- Sensitivity to heat (eg, during showers, sunlight exposure, vigorous exercise) for a few days